IndustryCompany release

Rocket Pharmaceuticals reports FDA alignment on RP-A501 pivotal Danon trial design in Q3 update

🇺🇸 Rocket Pharmaceuticals, Inc. (RCKT) · Thu 12 Nov 2026

The gene therapy developer says the FDA agreed the pivotal Phase 2 design for RP-A501 and that KRESLADI is commercially ready, with cash expected to last into Q3 2028.

Rocket Pharmaceuticals said on 12 November 2026 that the US Food and Drug Administration has aligned with it on the design of the pivotal Phase 2 trial of RP-A501 in Danon disease. The company expects dosing in the trial to be completed by mid-2027.

In its third-quarter 2026 results, Rocket reported a net loss of $49.2m and cash of $279.4m. It said this cash should fund operations into the third quarter of 2028.

The company also began dosing in the Phase 1 trial of RP-A701, a candidate for BAG3-associated dilated cardiomyopathy (BAG3-DCM). RP-A701 has received orphan designation from the European Commission. As general context, orphan designation in the EU is granted to medicines for rare, serious conditions and can bring development incentives.

On the commercial side, Rocket said KRESLADI is now commercially ready, with two Qualified Treatment Centers activated. The summary provided does not give further detail on launch timing, pricing or the centres involved.

What it means for your team

  • FDA agreement on the pivotal trial design for RP-A501 reduces one regulatory uncertainty, though the source gives no detail on endpoints or sample size.
  • The mid-2027 dosing completion target gives regulatory and market-access teams a first timeline marker for the Danon programme.
  • Activation of two Qualified Treatment Centers for KRESLADI points to a site-based delivery model that access and supply teams may need to follow.
  • The EC orphan designation for RP-A701 adds a European regulatory milestone to an early-stage BAG3-DCM programme.

Company's press release (SEC filing): Rocket Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Rocket Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →